Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The company used AI to prioritize the novel target as well as to generate and optimize the small molecule.
read more
The orally-available compound could provide an alternative to conventional glucocorticoids, the current standard of care.
read more
A rolling NDA submission for treatment-resistant depression with the FDA is underway.
read more
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks.
read more
Vertex will pick up an FDA-approved oral therapy for acromegaly and a phase 3 drug to treat CAH.
read more
The phase 1/2 study will evaluate the combo in EGFR-mutated and PD-L1 positive locally advanced or metastatic NSCLC.
read more
The retraction comes amid increasing regulatory scrutiny of the drug.
read more
Centanafadine was granted Priority Review and has a PDUFA target action date of July 24, 2026.
read more
The company is adding leading brands to its portfolio to boost its position in Belgium, Poland, and the Nordics.
read more
The phase 1b/2 trial will be the first time that an eIF2B is administered to people with VWM disease.
read more
DT120 is a lysergamide compound — an LSD derivative — administered as a single 100 µg orally disintegrating tablet.
read more
The company's proprietary drug delivery platform replaces daily pills with a once-monthly capsule that releases a stable dose.
read more
Complicated urinary tract infections have historically required IV treatment when standard oral options fail.
read more
The acquisition gives Lilly a pipeline of orally-available MNK inhibitors for treating chronic pain.
read more
The drugmaker will advance elecoglipron into an extensive phase 3 program in obesity and type 2 diabetes.
read more